https://orcid.org/0000-0002-7518-185X
References
- AbbVie Corporation. Product Monograph. Kaletra. Lopinavir/ritonavir [cited 2019, Sept 27]. Available from: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/KALETRA_PM_EN.pdf.
- Seminari E, Gentilini G, Galli L, et al. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother. 2005;56(4):790–792.
- Gutiérrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr. 2003;33(5):594–600.
- Phillips A. Important Safety Information Regarding a Drug Interaction Between Fluticasone Propionate (Flonase/Flovent/Advair) and Ritonavir (Norvir/Kaletra). Health Canada; 2004.
- Bayer HealthCare Pharmaceuticals Inc. Betapace (sotalol HCl) 2010. [cited 2019, Sept 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s019lbl.pdf.
- Schoergenhofer C, Jilma B, Stimpfl T, et al. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with Coronavirus Disease 2019 (COVID-19). Ann Intern Med. 2020;173(8):670–672.
- Gregoire M, Le Turnier P, Gaborit BJ, et al. Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother. 2020;75(9):2702–2704.
- Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–438.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
- Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.
- Holmstock N, Annaert P, Augustijns P. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice. Drug Metab Dispos. 2012;40(8):1473–1477.
- De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41(14):1135–1151.
- World Health Organization. “Solidarity” clinical trial for COVID-19 treatments 2020. [cited 2020, July 7]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.